CME

Host: Suzanne Kafaja, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Suzanne Kafaja, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Suzanne Kafaja, MD Host: Siyuan Cao, MD Host: Michael Lewis, MD Host: Rajan Saggar, MD Host: Shelley Shapiro, MD, PhD Host: Antoine Hage, MD Host: Richard N. Channick, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Christopher B. Cooper, MD, PhD Host: Alexander Sherman, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Christopher B. Cooper, MD, PhD Host: Alexander Sherman, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Adam J. Brownstein, MD This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event: Important advancements and updates across the PH disease spectrum The latest ERS/ESC guidelines for diagnosing and treating PH Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH Real-world examples and data related to all discussion topics

Host: Paul Paik, MD Guest: D. Ross Camidge, MD, PhD Guest: Keith Kerr, BSc, MB ChB Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.